Kura Oncology (NASDAQ:KURA) +7.9% pre-market after announcing data from a phase 2 clinical trial of its tipifarnib drug candidate in patients with relapsed or refractory peripheral T-cell lymphoma.
Kura says the results of the trial showed “ongoing anti-tumor activity and a manageable safety profile” in advanced patients with angioimmunoblastic T-cell lymphoma, as well as non-AITL relapsed or refractory peripheral T-cell lymphoma.
The company believes the data support the potential to register tipifarnib in both the AITL and PTCL-NOS patient populations, and plans to seek regulatory feedback on next steps for the program.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.